PainChek Management
Management criteria checks 3/4
PainChek's CEO is Philip Daffas, appointed in Sep 2016, has a tenure of 8.25 years. total yearly compensation is A$434.36K, comprised of 52.5% salary and 47.5% bonuses, including company stock and options. directly owns 1.55% of the company’s shares, worth A$632.76K. The average tenure of the management team and the board of directors is 3.8 years and 8.3 years respectively.
Key information
Philip Daffas
Chief executive officer
AU$434.4k
Total compensation
| CEO salary percentage | 52.5% |
| CEO tenure | 8.3yrs |
| CEO ownership | 1.5% |
| Management average tenure | 3.8yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
We're Keeping An Eye On PainChek's (ASX:PCK) Cash Burn Rate
Jul 04
Is PainChek (ASX:PCK) In A Good Position To Invest In Growth?
Feb 08Will PainChek (ASX:PCK) Spend Its Cash Wisely?
Jul 05Companies Like PainChek (ASX:PCK) Can Afford To Invest In Growth
Jan 26We're Interested To See How PainChek (ASX:PCK) Uses Its Cash Hoard To Grow
Sep 07When Can We Expect A Profit From PainChek Limited (ASX:PCK)?
May 07PainChek (ASX:PCK) Is In A Strong Position To Grow Its Business
Mar 01Market Sentiment Around Loss-Making PainChek Limited (ASX:PCK)
Nov 20CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$434k | AU$228k | -AU$8m |
| Mar 31 2024 | n/a | n/a | -AU$8m |
| Dec 31 2023 | n/a | n/a | -AU$8m |
| Sep 30 2023 | n/a | n/a | -AU$8m |
| Jun 30 2023 | AU$431k | AU$226k | -AU$8m |
| Mar 31 2023 | n/a | n/a | -AU$7m |
| Dec 31 2022 | n/a | n/a | -AU$7m |
| Sep 30 2022 | n/a | n/a | -AU$6m |
| Jun 30 2022 | AU$411k | AU$227k | -AU$6m |
| Mar 31 2022 | n/a | n/a | -AU$6m |
| Dec 31 2021 | n/a | n/a | -AU$7m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$470k | AU$232k | -AU$6m |
| Mar 31 2021 | n/a | n/a | -AU$5m |
| Dec 31 2020 | n/a | n/a | -AU$4m |
| Sep 30 2020 | n/a | n/a | -AU$8m |
| Jun 30 2020 | AU$4m | AU$319k | -AU$12m |
| Mar 31 2020 | n/a | n/a | -AU$12m |
| Dec 31 2019 | n/a | n/a | -AU$12m |
| Sep 30 2019 | n/a | n/a | -AU$8m |
| Jun 30 2019 | AU$378k | AU$205k | -AU$3m |
| Mar 31 2019 | n/a | n/a | -AU$3m |
| Dec 31 2018 | n/a | n/a | -AU$3m |
| Sep 30 2018 | n/a | n/a | -AU$4m |
| Jun 30 2018 | AU$402k | AU$205k | -AU$5m |
Compensation vs Market: Philip's total compensation ($USD270.46K) is about average for companies of similar size in the Australian market ($USD290.31K).
Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.
CEO
Philip Daffas
8.3yrs
Tenure
AU$434,361
Compensation
Mr. Philip Daffas, BSc, Dip EENG, MBA, GAICD, has been Managing Director and Director at PainChek Limited since September 30, 2016 and serves as its Chief Executive Officer. Mr. Daffas served as Vice Presi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 8.3yrs | AU$434.36k | 1.55% A$ 632.8k | |
| Chief Financial Officer | 3.8yrs | AU$327.08k | 0.015% A$ 6.2k | |
| Manager & Head of Operations | 3.8yrs | no data | no data | |
| Chief Technology Officer | 7.7yrs | no data | no data | |
| Chief Scientific Officer | no data | no data | no data | |
| Head of Business Development | no data | no data | no data | |
| Company Secretary | less than a year | no data | no data |
3.8yrs
Average Tenure
Experienced Management: PCK's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 8.3yrs | AU$434.36k | 1.55% A$ 632.8k | |
| Non-Executive Chairman of the Board | 8.3yrs | AU$118.75k | 1.04% A$ 425.3k | |
| Non-Executive Director | 10.3yrs | AU$59.37k | 0.90% A$ 368.3k | |
| Non-Executive Director | 8.3yrs | AU$59.37k | 0.62% A$ 255.0k | |
| Non-Executive Director | 2.8yrs | AU$59.37k | 0.16% A$ 66.2k | |
| Member of Clinical Advisory Board | 6.5yrs | no data | no data |
8.3yrs
Average Tenure
79yo
Average Age
Experienced Board: PCK's board of directors are considered experienced (8.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 19:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PainChek Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martyn Jacobs | Canaccord Genuity |
| Ian Martin | New Street Research LLP |